Current biological implications and clinical relevance of metastatic circulating tumor cells.

Autor: Shahhosseini R; Faculty of Medicine, Istanbul Medipol University, Istanbul, Turkey., Pakmehr S; School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran.; Ahvaz Jundishapur University of Medical Sciences Ahvaz, Ahvaz, Iran., Elhami A; School of Medicine, Shiraz University of Medical Sciences, Shiraz, Iran., Shakir MN; Department of Medical Laboratories Technology, AL-Nisour University College, Baghdad, Iraq., Alzahrani AA; Department of Surgery, College of Medicine, Taif University, Taif, Saudi Arabia., Al-Hamdani MM; Pharmaceutics Department, College of Pharmacy, Al-Ayen University, Thi-Qar, Iraq., Abosoda M; College of Pharmacy, The Islamic University, Najaf, Iraq.; College of Pharmacy, The Islamic University of Al Diwaniyah, Al Diwaniyah, Iraq.; College of Pharmacy, The Islamic University of Babylon, Babylon, Iraq., Alsalamy A; College of Pharmacy, Imam Ja'afar Al-Sadiq University, Al-Samawa, Al-Muthanna, 66002, Iraq., Mohammadi-Dehcheshmeh M; Department of Biology, Sciences and Arts University, Yazd, Iran., Maleki TE; Shahid Beheshti University of Medical Sciences, Tehran, Iran. ezazi.sbmu2015@gmail.com., Saffarfar H; Cardiovascular Research Center, Tehran University of Medical Sciences, Tehran, Iran. dr.h.saffarfar@gmail.com., Ali-Khiavi P; Medical Faculty, Tabriz University of Medical Sciences, Tabriz, Iran.
Jazyk: angličtina
Zdroj: Clinical and experimental medicine [Clin Exp Med] 2024 Nov 15; Vol. 25 (1), pp. 7. Date of Electronic Publication: 2024 Nov 15.
DOI: 10.1007/s10238-024-01518-6
Abstrakt: Metastatic disease and cancer recurrence are the primary causes of cancer-related deaths. Circulating tumor cells (CTCs) and disseminated tumor cells (DTCs) are the driving forces behind the spread of cancer cells. The emergence and development of liquid biopsy using rare CTCs as a minimally invasive strategy for early-stage tumor detection and improved tumor management is a promising advancement in recent years. However, before blood sample analysis and clinical translation, precise isolation of CTCs from patients' blood based on their biophysical properties, followed by molecular identification of CTCs using single-cell multi-omics technologies is necessary to understand tumor heterogeneity and provide effective diagnosis and monitoring of cancer progression. Additionally, understanding the origin, morphological variation, and interaction between CTCs and the primary and metastatic tumor niche, as well as and regulatory immune cells, will offer new insights into the development of CTC-based advanced tumor targeting in the future clinical trials.
Competing Interests: Declarations Conflict of interests The authors declare no competing interests. Ethical approval This article does not contain any studies with human participants or animals performed by any of the authors. Consent to participate Not applicable. Consent to publish Not applicable.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: